

CLAIMS

1. The use of (i) an antibody specific for *Yersinia pestis* Fl-antigen, or a binding fragment thereof, or (ii) an antibody
5 specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, or a combination of (i) and (ii), in the production of a medicament for the treatment of infection by *Yersinia pestis*.
2. The use according to claim 1 wherein a combination of (i)
10 and (ii) is used.
3. The use according to claim 2 wherein the said combination comprises an antibody specific for *Yersinia pestis* Fl-antigen, and an antibody specific for *Yersinia pestis* V-antigen.
- 15 4. The use according to any one of the preceding claims wherein the antibodies are monoclonal antibodies.
5. The use according to any one of the preceding claims
20 wherein the medicament is for administration up to about 48 hours post-infection.
6. The use according to any one of the preceding claims wherein the antibody specific for *Yersinia pestis* V-antigen or
25 binding fragment thereof specifically binds an epitope of the V-antigen found between amino acids 135-275 of the sequence of the V-antigen.
7. The use according to any one of the preceding claims
30 wherein the antibodies or binding fragments thereof, are humanised.
8. A method of treating a human or animal suffering from the effects of infection with *Yersinia pestis*, said method
35 comprising administering to the human or animal, a therapeutically effective amount of (i) an antibody specific for

Yersinia pestis Fl-antigen, or a binding fragment thereof, or
(ii) an antibody specific for *Yersinia pestis* V-antigen, or a
binding fragment thereof, or a combination of (i) and (ii).

- 5 9. A method according to claim 8 wherein the method comprises
administering a combination of (i) and (ii).

- 10 10. A pharmaceutical composition comprising an antibody
specific for the *Yersinia pestis* V-antigen or a binding fragment
thereof, an antibody specific for the *Yersinia pestis* Fl-antigen
or a binding fragment thereof and a pharmaceutically acceptable
carrier.

11. A pharmaceutical composition according to claim 10 wherein
15 the antibodies are monoclonal antibodies.

12. A pharmaceutical composition according to claim 10 or 11
wherein the antibody specific for *Yersinia pestis* V-antigen or
binding fragment thereof specifically binds an epitope of the V-
20 antigen found between amino acids 135-275 of the sequence of the
V-antigen.

13. A pharmaceutical composition according to any one of claims
10 to 12 wherein the antibodies or binding fragments thereof,
25 are humanised or are fully human.

14. A prophylactic vaccine for protection of a human or animal
against infection by *Yersinia pestis*, said vaccine comprising a
composition according to any one of claims 10 to 13.

- 30 15. A method of immunising against infection by *Yersinia pestis*
comprising administering a vaccine according to claim 14.

16. The use of a combination of an antibody specific for *Yersinia pestis* F1-antigen, or a binding fragment thereof, an antibody specific for *Yersinia pestis* V-antigen, or a binding fragment thereof, and a pharmaceutically acceptable carrier in
5 the production of a medicament for the passive immunisation of a human or animal against infection by *Yersinia pestis*.

ART 34 AMDT

AMENDED SHEET